BACKGROUND: The aim was to determine obestatin and ghrelin serum levels and their ratio in inflammatory bowel disease (IBD) patients. METHODS: We measured the ghrelin and obestatin levels of 31 Crohn's disease patients and 22 patients with ulcerative colitis using a radioimmunoassay method. Circulating levels of the 2 hormones and their ratio were correlated with the disease type and activity, disease localization, and treatment. RESULTS: The mean ghrelin value was statistically significantly higher in patients with active disease (402.4 +/- 462.6 pg/mL) than in patients in remission (148.2 +/- 59.6 pg/mL) P = 0.0290, alpha = 0.05, whereas obestatin mean values were not (217.4 +/- 59.8 pg/mL in active disease and 189.0 +/- 46.8 pg/mL in patients with inactive disease P = 0.0607). When we evaluated the obestatin/ghrelin ratio between active and inactive disease, it was found that the ratio in active disease was statistically significantly lower (0.8 +/- 0.3) than in patients in remission (1.4 +/- 0.3) P < 0.001, alpha = 0.05. There is also a statistically significantly correlation between obestatin/ghrelin ratio and disease activity (P < 0,001). CONCLUSIONS: Ghrelin and obestatin seem to play a significant role in IBD pathogenesis. Further studies are needed to elucidate the role of these hormones as new biological markers of activity of IBD.
BACKGROUND: The aim was to determine obestatin and ghrelin serum levels and their ratio in inflammatory bowel disease (IBD) patients. METHODS: We measured the ghrelin and obestatin levels of 31 Crohn's diseasepatients and 22 patients with ulcerative colitis using a radioimmunoassay method. Circulating levels of the 2 hormones and their ratio were correlated with the disease type and activity, disease localization, and treatment. RESULTS: The mean ghrelin value was statistically significantly higher in patients with active disease (402.4 +/- 462.6 pg/mL) than in patients in remission (148.2 +/- 59.6 pg/mL) P = 0.0290, alpha = 0.05, whereas obestatin mean values were not (217.4 +/- 59.8 pg/mL in active disease and 189.0 +/- 46.8 pg/mL in patients with inactive disease P = 0.0607). When we evaluated the obestatin/ghrelin ratio between active and inactive disease, it was found that the ratio in active disease was statistically significantly lower (0.8 +/- 0.3) than in patients in remission (1.4 +/- 0.3) P < 0.001, alpha = 0.05. There is also a statistically significantly correlation between obestatin/ghrelin ratio and disease activity (P < 0,001). CONCLUSIONS:Ghrelin and obestatin seem to play a significant role in IBD pathogenesis. Further studies are needed to elucidate the role of these hormones as new biological markers of activity of IBD.
Authors: Firas A Ghomraoui; Sami T Alotaibi; Meshal A Alharthi; Saeed S Asiri; Majid A Almadi; Othman R Alharbi; Nahla A Azzam; Abdulrahman M Aljebreen; Maria Saeed; Baraa Hajkhder; Waleed Saeed; Mohammad A Alzoghaibi Journal: Saudi J Gastroenterol Date: 2017 May-Jun Impact factor: 2.485
Authors: Aleksandra Matuszyk; Piotr Ceranowicz; Zygmunt Warzecha; Jakub Cieszkowski; Joanna Bonior; Jolanta Jaworek; Beata Kuśnierz-Cabala; Peter Konturek; Tadeusz Ambroży; Artur Dembiński Journal: Oxid Med Cell Longev Date: 2015-12-20 Impact factor: 6.543
Authors: Aleksandra Matuszyk; Piotr Ceranowicz; Zygmunt Warzecha; Jakub Cieszkowski; Krystyna Gałązka; Joanna Bonior; Jolanta Jaworek; Peter Christopher Konturek; Krzysztof Gil; Artur Dembiński Journal: Arch Med Sci Date: 2016-03-23 Impact factor: 3.318
Authors: Katarzyna Konarska; Jakub Cieszkowski; Zygmunt Warzecha; Piotr Ceranowicz; Anna Chmura; Beata Kuśnierz-Cabala; Krystyna Gałązka; Paweł Kowalczyk; Andrzej Miskiewicz; Thomas Jan Konturek; Michał Pędziwiatr; Artur Dembiński Journal: Int J Mol Sci Date: 2018-06-01 Impact factor: 5.923